US 12,133,912 B2
Stable pharmaceutical compositions of succinylcholine chloride
Ashish Anilrao Dubewar, Hyderabad (IN); Amit Anil Charkha, Wardha (IN); Sumitra Ashokkumar Pillai, Hyderabad (IN); Pradeep Kumar Kare, Hyderabad (IN); Kumar Swamy Ummiti, Hyderabad (IN); Shanker Mamidi, Nalgonda (IN); and Mayur Anshiram Adhav, Hyderabad (IN)
Assigned to Slayback Pharma LLC., Princeton, NJ (US)
Filed by Slayback Pharma LLC., Princeton, NJ (US)
Filed on Dec. 4, 2023, as Appl. No. 18/528,684.
Application 18/528,684 is a continuation of application No. 17/822,756, filed on Aug. 26, 2022, granted, now 11,872,305.
Claims priority of application No. 202141038846 (IN), filed on Aug. 27, 2021.
Prior Publication US 2024/0108571 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 37/00 (2006.01); A01N 25/00 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 9/00 (2006.01); A61K 31/215 (2006.01); A61K 31/221 (2006.01); A61K 31/225 (2006.01); A61K 31/24 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01)
CPC A61K 9/0019 (2013.01) [A61K 31/221 (2013.01); A61K 31/225 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01)] 1 Claim
 
1. A pharmaceutical composition consisting of:
(i) therapeutically effective amount of succinylcholine chloride at a concentration of from about 5 mg/mL to 60 mg/mL;
(ii) propylene glycol as a stabilizing agent at a concentration of from about 20 mg/mL to about 300 mg/mL;
(iii) water as a solvent,
(iv) optionally one or more pH adjusting agents; and
(v) optionally sodium chloride as a tonicity contributing agent at a concentration of from about 1 mg/mL to about 50 mg/mL,
wherein the composition is in the form of a ready to use aqueous solution suitable for parenteral administration, and
wherein the aqueous solution is stable at room temperature for at least 30 days.